Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Immunology ; 120(4): 526-35, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17343615

ABSTRACT

Oligodeoxynucleotides (ODN) with unmethylated deoxycytidyl-deoxyguanosine dinucleotides (CpG-ODNs) stimulate Toll-like receptor 9 (TLR9) in plasmacytoid dendritic cells (pDC) and B cells and activate innate and adaptive immunity. Three classes of synthetic CpG-ODNs, class A, B and C, activate cells through TLR9; our goal was to evaluate their effect on cells from human immunodeficiency virus (HIV)-1(+) individuals. We compared the frequencies and the unstimulated activation status of immune effector cells in HIV-1(+) and HIV-1(-) individuals. Fewer pDC, myeloid dendritic cells (mDC), B cells, natural killer (NK) cells and invariant natural killer T cells (iNKT) were present in HIV-1(+) peripheral blood mononuclear cells (PBMC) and their baseline activation status was higher than HIV-1(-) PBMC. Exposure of HIV-1(+) PBMC to all classes of CpG-ODNs led to activation and maturation of pDC based on CD86, CD80, and CD83 expression similar to that of cells from HIV-1(-) individuals. The percentage of CpG-ODN stimulated pDC that express CD40 was dramatically higher when cells were obtained from HIV-1(+) than from HIV-1(-) individuals. B-lymphocytes were activated similarly in HIV-1(+) and HIV-1(-) individuals. mDC, NK and iNKT cell, which lack TLR9, were indirectly activated. Interferon-alpha (IFN-alpha) and interferon inducible protein 10 (IP-10) secretion was induced by class A or C but not class B CpG-ODN, but the concentrations were less than those produced by HIV-1(-) PBMC. HIV-1 infected individuals have fewer innate effector cells that are chronically activated, but these cells can be further activated by CpG-ODN, which suggests that synthetic CpG-ODNs could be used to enhance the immune system in HIV-1 infected individuals.


Subject(s)
HIV Infections/immunology , HIV-1 , Oligodeoxyribonucleotides/immunology , Adult , B-Lymphocytes/immunology , CD4 Lymphocyte Count , Cells, Cultured , Chemokine CXCL10 , Chemokines, CXC/biosynthesis , Dendritic Cells/immunology , Female , Flow Cytometry , HIV Infections/virology , Humans , Immunity, Cellular , Interferon-alpha/biosynthesis , Killer Cells, Natural/immunology , Lymphocyte Activation/immunology , Male , Middle Aged , Toll-Like Receptor 9/immunology , Viral Load
2.
Cell Immunol ; 250(1-2): 75-84, 2007.
Article in English | MEDLINE | ID: mdl-18334250

ABSTRACT

We compared TLR responsiveness in PBMC from HIV-1-infected and uninfected individuals using the TLR agonists: TLR7 (3M-001), TLR8 (3M-002), and TLR7/8 (3M-011). Activation and maturation of plasmacytoid dendritic cells (pDC) were measured by evaluating CD86, CD40, and CD83 expression and myeloid dendritic cell (mDC) activation was measured by evaluating CD40 expression. All agonists tested induced activation and maturation of pDC in PBMC cultures of cells from HIV+ and HIV- individuals. The TLR7 agonist induced significantly less pDC maturation in cells from HIV+ individuals. Quantitative assessment of secreted IFN-alpha and pro-inflammatory cytokines at the single cell level showed that pDC from HIV+ individuals stimulated with TLR7 and TLR7/8 induced IFN-alpha. TLR8 and TLR7/8 agonists induced IL-12 and COX-2 expression in mDC from HIV+ and HIV- individuals. Understanding pDC and mDC activation and maturation in HIV-1 infection could lead to more rational development of immunotherapeutic strategies to stimulate the adaptive immune response to HIV-1.


Subject(s)
Dendritic Cells/immunology , HIV Infections/immunology , HIV-1/immunology , Imidazoles/pharmacology , Quinolines/pharmacology , Toll-Like Receptor 7/agonists , Toll-Like Receptor 8/agonists , Cells, Cultured , Cyclooxygenase 2/metabolism , Dendritic Cells/virology , Female , Flow Cytometry , Humans , Interferon-alpha/drug effects , Interferon-alpha/metabolism , Interleukin-12/metabolism , Ligands , Male , Toll-Like Receptor 7/immunology , Toll-Like Receptor 8/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...